

Pharmaceutical Benefits Advisory Committee

Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 JUNE 2024

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

Item

PBAC Advice

Ketoconazole

The sponsor requested the delisting of Nizoral[®] 2% cream (ketoconazole) from the Pharmaceutical Benefits Scheme (PBS).

The Pharmaceutical Benefits Advisory Committee (PBAC) noted the sponsor's plans to discontinue manufacture of Nizoral 2% cream and that there are alternative products available on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need.



Vanessa McMahon
Director, PBAC Assessment Section
Office of Health Technology Assessment
Technology Assessment and Access Division
16 May 2024